Compare HVT & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HVT | PALI |
|---|---|---|
| Founded | 1885 | 1996 |
| Country | United States | United States |
| Employees | 2392 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.8M | 359.7M |
| IPO Year | N/A | 2019 |
| Metric | HVT | PALI |
|---|---|---|
| Price | $24.98 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.29 |
| AVG Volume (30 Days) | 87.2K | ★ 2.4M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.05% | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | $8.83 | N/A |
| Revenue Next Year | $8.70 | N/A |
| P/E Ratio | $22.08 | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $19.53 | $0.55 |
| 52 Week High | $27.67 | $2.86 |
| Indicator | HVT | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 66.44 | 47.10 |
| Support Level | $20.16 | $1.78 |
| Resistance Level | $25.27 | $2.17 |
| Average True Range (ATR) | 0.72 | 0.12 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 75.04 | 43.59 |
Haverty Furniture Companies Inc is a specialty retailer of residential furniture and accessories. It provides various products such as Sofa Tables, Sleepers, End Tables, Cocktail Tables, Accent Pieces, Display Cabinets, Wall Decor, floral and Tress, and other related products. The company operates in the Southern and Midwestern U.S. All its activities are encompassed in its Merchandise division. The company derives the majority of revenue from its upholstery products and, secondarily, from bedroom furniture.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.